Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Long-term immune reconstitution in patients treated with autologous stem cell transplantation for refractory autoimmune diseases
    T Alexander
    G Massenkeil
    GR Burmester
    A Radbruch
    R Arnold
    F Hiepe
    A Thiel
    Arthritis Res Ther, 6
  • [42] Long-term immune reconstitution in patients treated with autologous stem cell transplantation for refractory autoimmune diseases
    Arnold, R
    Alexander, T
    Massenkeil, G
    Burmester, R
    Radbruch, A
    Hiepe, F
    Thiel, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S143 - S144
  • [43] Hematopoietic stem cell transplantation in the treatment of autoimmune diseases
    Kozák, T
    WIENER KLINISCHE WOCHENSCHRIFT, 2002, 114 (1-2) : 7 - 13
  • [44] Haematopoietic stem cell transplantation in the treatment of autoimmune diseases
    Mahevas, M.
    Vaida, I.
    Le Page, L.
    Sid-Idris, S.
    Royer, B.
    Garedi, R.
    Damaj, G.
    Duhaut, P.
    Claisse, J. -F
    Ducroix, J. -P.
    Marolleau, J. -P.
    REVUE DE MEDECINE INTERNE, 2008, 29 (02): : 115 - 121
  • [45] Long-term immune reconstitution in patients treated with autologous stem cell transplantation for refractory autoimmune diseases
    Alexander, T
    Massenkeil, G
    Burmester, G
    Radbruch, A
    Arnold, R
    Hiepe, F
    Thiel, A
    ARTHRITIS RESEARCH & THERAPY, 2004, 6 (Suppl 1) : S28 - S28
  • [46] Treatment of autoimmune diseases by hematopoietic stem cell transplantation
    Ikehara, S
    EXPERIMENTAL HEMATOLOGY, 2001, 29 (06) : 661 - 669
  • [47] Autologous stem cell transplant in 3 patients with refractory autoimmune diseases.
    Lee, TL
    Chan, GC
    Ha, SY
    Ho, HK
    Chiang, AKS
    Lau, YL
    BLOOD, 2003, 102 (11) : 484B - 485B
  • [48] Atrial Fibrillation After Autologous Hematopoietic Stem Cell Transplantation (AHSCT)
    Orozco Araujo, Silvana
    Ochoa Montes, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S278
  • [49] Induction of remission in refractory autoimmune disease by autologous stem cell transplantation (ASCT).
    Rosen, O
    Massenkeil, G
    Haupl, T
    Hiepe, F
    Burmester, G
    Gromnica-Ihle, E
    Kalus, U
    Radtke, H
    Thiel, A
    Radbruch, A
    Arnold, R
    BLOOD, 1998, 92 (10) : 372B - 372B
  • [50] Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis
    Kim, KC
    Lee, IH
    Choi, JH
    Oh, MR
    Ahn, MJ
    Kim, SY
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (01) : 129 - 132